Evidence map›Paper›PMID 27253171›Full record

Trial reportBritish journal of cancer2016

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.

F Mouriaux, V Servois, J J Parienti, T Lesimple, A Thyss, C Dutriaux, E M Neidhart-Berard, N Penel, C Delcambre, L Peyro Saint Paul and 4 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02517736 (Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02517736 phase2completednot on this map

Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination

TypeinterventionalSponsorUniversity Hospital, CaenRan2012 to 2015Enrolled32ConditionsUveal MelanomaArmsSorafenib at a dose of 800 mg / day
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Management of liver metastases from uveal melanoma.The British journal of surgery · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.Therapeutic advances in medical oncology · 2023
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Hypoxia-dependent drivers of melanoma progression.Journal of experimental & clinical cancer research : CR · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 3 countries.

F MouriauxService d'ophtalmologie (Department of Ophthalmology), CHU Rennes, 35033 Rennes, France.
V ServoisInstitut Curie, Département d'Imagerie Médicale (Curie Institute, Department of Medical Imaging), F-75005 Paris, France.
J J ParientiCHU Caen, F-14033 Caen France.
T LesimpleCentre Eugène Marquis, F-35000 Rennes, France.
A ThyssCentre Antoine Lacassagne, F-06000 Nice, France.
C DutriauxService Dermatologie (Dermatology Department), CHU de Bordeaux, F-33000 Bordeaux, France.
E M Neidhart-BerardCentre Léon Bérard, F-69000 Lyon, France.
N PenelCentre Oscar Lambret, F-59000 Lille, France.
C DelcambreCentre François Baclesse, F-14000 Caen France.
L Peyro Saint PaulCHU Caen, F-14033 Caen France.
A D PhamCHU Caen, F-14033 Caen France.
N HeutteCentre François Baclesse, F-14000 Caen France.
S Piperno-NeumannDépartement d'Oncologie Médicale, Institut Curie, (Department of Medical Oncology, Curie Institute), 75005 Paris, France.
F JolyCHU Caen, F-14033 Caen France.
Centre François Baclesse · LUCentre Hospitalier Universitaire de Caen Normandie · FRCentre Antoine Lacassagne · FRCentre de Radiothérapie Bayard · FRCentre Eugène Marquis · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Léon Bérard · FRCentre Oscar Lambret · FRInstitut Curie · FRUniversité Rennes 2 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the study was to analyse efficacy, safety, and health-related quality of life (HRQoL) for sorafenib treatment in patients with metastatic uveal melanoma.

methodsA multicentre, single-arm phase II trial was conducted. The primary objective was to determine the non-progression rate (RECIST) at 24 weeks for patients receiving sorafenib at a dose of 800 mg per day. Secondary endpoints included progression-free survival (PFS), overall survival (OS), toxicity, and HRQoL.

resultsThirty-two patients were included. Ten patients showed non-progression at 24 weeks (31.2%) without objective tumour responses. The estimated 24-week PFS was 31.2% (95% CI: 14.8%-47.6%) and the estimated 24-week OS was 62.5% (95% CI: 45.4%-79.6%). Ten patients (34.3%) had at least one grade 3 or 4 adverse reaction and 12 patients (41.4%) required dose modifications due to toxicity. At 24 weeks, no patient had an improvement in global HRQoL and 87.5% experienced a permanent increase in physical fatigue.

conclusionsSorafenib demonstrated non-progression at 24 weeks in 31.2% of patients. However, 41.4% of patients required dose modifications due to toxicity and no improvement in HRQoL was demonstrated.

Indexed as

AgedAntineoplastic AgentsDisease-Free SurvivalFemaleHumansMaleMelanomaNiacinamidePhenylurea CompoundsQuality of LifeSorafenibUveal MelanomaUveal NeoplasmsAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenib

Identifiers

PMID27253171
PMCPMC4931363
OpenAlexW2418450403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.